RNXT Valuation
RenovoRx Inc
$
0.990
- Overview
- Forecast
- Valuation
RNXT Relative Valuation
RNXT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNXT is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.15
P/B
Median3y
147.32
Median5y
120.16
-25.78
FCF Yield
Median3y
-45.66
Median5y
-40.00
Competitors Valuation Multiple
The average P/S ratio for RNXT's competitors is 15.13, providing a benchmark for relative valuation. RenovoRx Inc Corp (RNXT) exhibits a P/S ratio of 20.87, which is 37.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
PACB
Pacific Biosciences of California Inc
1.130
USD
+1.80%
MUX
McEwen Mining Inc
7.540
USD
+0.27%
AAM
AA Mission Acquisition Corp
10.320
USD
0.00%
MREO
Mereo BioPharma Group PLC
2.600
USD
0.00%
LAES
Sealsq Corp
2.522
USD
+1.29%
WDH
Waterdrop Inc
1.340
USD
+0.37%
CVGW
Calavo Growers Inc
27.020
USD
0.00%
MTLS
Materialise NV
5.250
USD
+1.16%
FC
Franklin Covey Co
20.790
USD
+0.97%
AKBA
Akebia Therapeutics Inc
2.405
USD
+0.63%
FAQ
Is RenovoRx Inc (RNXT) currently overvalued or undervalued?
RenovoRx Inc (RNXT) is now in the Fair zone, suggesting that its current forward PS ratio of 20.87 is considered Fairly compared with the five-year average of 0.71. The fair price of RenovoRx Inc (RNXT) is between to according to relative valuation methord.
What is RenovoRx Inc (RNXT) fair value?
How does RNXT's valuation metrics compare to the industry average?
What is the current P/B ratio for RenovoRx Inc (RNXT) as of May 02 2025?
What is the current FCF Yield for RenovoRx Inc (RNXT) as of May 02 2025?
What is the current Forward P/E ratio for RenovoRx Inc (RNXT) as of May 02 2025?